Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 31 Oct 2023 07:00 CET |
ULTIMOVACS | Ultimovacs Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 25 Oct 2023 17:50 CEST |
ULTIMOVACS | Ultimovacs Announces Webcast to Elaborate on the Results from Randomized UV1 Phase II NIPU Trial in Malignant Mesothelioma | 20103010 Biotechnology | Non-regulatory press releases |
| 23 Oct 2023 07:00 CEST |
ULTIMOVACS | Ultimovacs Provides Complete Phase II NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients with Malignant Mesothelioma Receiving UV1 Cancer Vaccine | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 17 Oct 2023 18:00 CEST |
ULTIMOVACS | Ultimovacs Announces NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients Receiving UV1 Cancer Vaccine in Phase II NIPU Trial in Malignant Mesothelioma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 12 Oct 2023 07:00 CEST |
ULTIMOVACS | Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma: Demonstrating Sustained Long-Term Overall Survival in Patients Treated with UV1 Cancer Vaccine | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 09 Oct 2023 07:00 CEST |
ULTIMOVACS | Ultimovacs Receives FDA Orphan Drug Designation for the UV1 Cancer Vaccine for Treatment of Mesothelioma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 27 Sep 2023 16:31 CEST |
ULTIMOVACS | Ultimovacs Announces that the Results from UV1 Phase II Clinical Trial NIPU in Malignant Mesothelioma will be Presented at the ESMO Congress 2023 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 22 Aug 2023 08:00 CEST |
ULTIMOVACS | Ultimovacs ASA Reports Second Quarter 2023 Financial Results and Provides General Business Update | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 16 Aug 2023 08:00 CEST |
ULTIMOVACS | Ultimovacs ASA: Invitation to second quarter 2023 results webcast presentation | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 03 Aug 2023 08:00 CEST |
ULTIMOVACS | Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 Jun 2023 16:30 CEST |
ULTIMOVACS | Ultimovacs Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 22 Jun 2023 15:30 CEST |
ULTIMOVACS | Ultimovacs' Chief Scientific Officer Gustav Gaudernack Receives Norwegian Tech Award's Honorary Prize as an Outstanding Pioneer Against Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 19 Jun 2023 07:00 CEST |
ULTIMOVACS | Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 08 Jun 2023 14:34 CEST |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 08 Jun 2023 12:22 CEST |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 07 Jun 2023 19:08 CEST |
ULTIMOVACS | Ultimovacs provides update on Phase II NIPU trial evaluating UV1 in second-line patients with malignant pleural mesothelioma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 10 May 2023 08:00 CEST |
ULTIMOVACS | Ultimovacs ASA Reports First Quarter 2023 Financial Results and Provides General Business Update | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 03 May 2023 08:00 CEST |
ULTIMOVACS | Ultimovacs ASA: Invitation to first quarter 2023 results webcast presentation | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 25 Apr 2023 07:00 CEST |
ULTIMOVACS | Ultimovacs provides updated guidance on timeline for readout of INITIUM Phase II clinical trial of UV1 in malignant melanoma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 21 Apr 2023 16:30 CEST |
ULTIMOVACS | Ultimovacs ASA - Share Option Program | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 20 Apr 2023 15:08 CEST |
ULTIMOVACS | Ultimovacs ASA - Annual General Meeting held on 20 April 2023 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 14 Apr 2023 08:00 CEST |
ULTIMOVACS | Ultimovacs ASA - Disclosure of voting rights of Annual General Meeting | 20103010 Biotechnology | Total number of voting rights and capital |
| 13 Apr 2023 11:31 CEST |
ULTIMOVACS | Ultimovacs Receives Intention to Grant Notice on European Patent on UV1 Cancer Vaccine-Checkpoint Inhibitor Combinations | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 24 Mar 2023 11:00 CET |
ULTIMOVACS | Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 24 Mar 2023 08:00 CET |
ULTIMOVACS | Ultimovacs ASA: Annual Report 2022 | 20103010 Biotechnology | Annual financial and audit Reports |
| 27 Feb 2023 08:00 CET |
ULTIMOVACS | Ultimovacs to Present at Cowen Healthcare Conference | 20103010 Biotechnology | Non-regulatory press releases |
| 16 Feb 2023 08:00 CET |
ULTIMOVACS | Ultimovacs ASA Reports Fourth Quarter 2022 Financial Results and Provides General Business Update | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 09 Feb 2023 08:00 CET |
ULTIMOVACS | Ultimovacs ASA: Invitation to fourth quarter 2022 results webcast presentation | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Jan 2023 08:00 CET |
ULTIMOVACS | Ultimovacs Announces Completed Patient Recruitment in NIPU Phase II Clinical Trial of UV1 in Mesothelioma | - | Additional regulated information required to be disclosed under the laws of a Member State |
| 21 Dec 2022 10:27 CET |
ULTIMOVACS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 20 Dec 2022 08:00 CET |
ULTIMOVACS | Cemiplimab to replace pembrolizumab in UV1 Phase II LUNGVAC Trial | 20103010 Biotechnology | Non-regulatory press releases |
| 14 Dec 2022 08:00 CET |
ULTIMOVACS | Ultimovacs Announces Completed Patient Recruitment in TENDU Phase I Clinical Trial in Prostate Cancer | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 29 Nov 2022 17:00 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 21 Nov 2022 07:00 CET |
ULTIMOVACS | Ultimovacs ASA: New share capital registered | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 16 Nov 2022 11:56 CET |
ULTIMOVACS | Ultimovacs ASA: Share capital increase related to exercise of options | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 10 Nov 2022 17:00 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 10 Nov 2022 08:00 CET |
ULTIMOVACS | Ultimovacs ASA Reports Third Quarter 2022 Financial Results and Provides General Business Update | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 03 Nov 2022 08:00 CET |
ULTIMOVACS | Ultimovacs ASA: Invitation to Third quarter 2022 results webcast presentation | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 25 Oct 2022 08:00 CEST |
ULTIMOVACS | Ultimovacs Announces First Patient Randomized in Phase II LUNGVAC Trial of UV1 in Non-Small Cell Lung Cancer (NSCLC) | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 18 Oct 2022 08:00 CEST |
ULTIMOVACS | Ultimovacs Announces New UV1 Data Showing Enhanced Efficacy Including in Hard-to-Treat Cancer Patients, Supporting Broad Utility | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 05 Oct 2022 19:26 CEST |
ULTIMOVACS | Ultimovacs Announces Positive Three-Year Results of 71% Overall Survival Rate in Cohort 1 of UV1-103 Study in Metastatic Malignant Melanoma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 21 Sep 2022 16:30 CEST |
ULTIMOVACS | Ultimovacs Announces Plenary Oral Presentation of Phase I Melanoma Trial Results at the 19th International Congress of the Society for Melanoma Research (SMR) | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 12 Sep 2022 15:05 CEST |
ULTIMOVACS | Ultimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 09 Sep 2022 08:53 CEST |
ULTIMOVACS | Ultimovacs ASA: New share capital registered | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 05 Sep 2022 19:00 CEST |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 05 Sep 2022 16:30 CEST |
ULTIMOVACS | Ultimovacs ASA: Share capital increase related to exercise of options | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 22 Aug 2022 17:00 CEST |
ULTIMOVACS | Ultimovacs Strengthens IP Portfolio with the United States Patent and Trademark Office (USPTO) Notice of Allowance on UV1 Method Patent | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 19 Aug 2022 08:00 CEST |
ULTIMOVACS | Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 18 Aug 2022 08:00 CEST |
ULTIMOVACS | Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 12 Aug 2022 08:00 CEST |
ULTIMOVACS | Ultimovacs ASA: Invitation to second quarter 2022 results webcast presentation | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |